S&P 500   3,123.95 (+0.06%)
DOW   27,957.38 (-0.28%)
QQQ   203.60 (+0.26%)
CGC   15.37 (+8.09%)
BABA   184.17 (-0.24%)
GE   11.48 (+0.35%)
T   38.14 (-3.78%)
ACB   2.40 (+5.25%)
F   8.89 (-0.67%)
PRI   132.20 (+0.84%)
BAC   32.94 (-0.06%)
DIS   148.55 (+0.61%)
S&P 500   3,123.95 (+0.06%)
DOW   27,957.38 (-0.28%)
QQQ   203.60 (+0.26%)
CGC   15.37 (+8.09%)
BABA   184.17 (-0.24%)
GE   11.48 (+0.35%)
T   38.14 (-3.78%)
ACB   2.40 (+5.25%)
F   8.89 (-0.67%)
PRI   132.20 (+0.84%)
BAC   32.94 (-0.06%)
DIS   148.55 (+0.61%)
S&P 500   3,123.95 (+0.06%)
DOW   27,957.38 (-0.28%)
QQQ   203.60 (+0.26%)
CGC   15.37 (+8.09%)
BABA   184.17 (-0.24%)
GE   11.48 (+0.35%)
T   38.14 (-3.78%)
ACB   2.40 (+5.25%)
F   8.89 (-0.67%)
PRI   132.20 (+0.84%)
BAC   32.94 (-0.06%)
DIS   148.55 (+0.61%)
S&P 500   3,123.95 (+0.06%)
DOW   27,957.38 (-0.28%)
QQQ   203.60 (+0.26%)
CGC   15.37 (+8.09%)
BABA   184.17 (-0.24%)
GE   11.48 (+0.35%)
T   38.14 (-3.78%)
ACB   2.40 (+5.25%)
F   8.89 (-0.67%)
PRI   132.20 (+0.84%)
BAC   32.94 (-0.06%)
DIS   148.55 (+0.61%)
Log in

Fate Therapeutics Price Target & Analyst Ratings (NASDAQ:FATE)

$14.54
+0.24 (+1.68 %)
(As of 11/19/2019 03:15 PM ET)
Today's Range
$14.19
Now: $14.54
$14.89
50-Day Range
$13.63
MA: $14.71
$15.81
52-Week Range
$11.00
Now: $14.54
$22.82
Volume39,566 shs
Average Volume600,875 shs
Market Capitalization$1.10 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.81

Analyst Ratings

Fate Therapeutics (NASDAQ:FATE) Price Target and Consensus Rating

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
16 Wall Street analysts have issued ratings and price targets for Fate Therapeutics in the last 12 months. Their average twelve-month price target is $24.94, suggesting that the stock has a possible upside of 71.51%. The high price target for FATE is $32.00 and the low price target for FATE is $16.00. There are currently 2 hold ratings and 14 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.882.943.002.88
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
15 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
13 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $24.94$25.00$25.00$19.63
Price Target Upside: 71.51% upside60.98% upside29.87% upside17.44% upside

Fate Therapeutics (NASDAQ:FATE) Consensus Price Target History

Average Share Price and Price Target by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Fate Therapeutics (NASDAQ:FATE) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/12/2019SunTrust BanksInitiated CoverageBuy$25.00Low
11/6/2019BMO Capital MarketsLower Price TargetOutperform$27.00 ➝ $26.00High
11/6/2019MizuhoDowngradeBuyHigh
11/6/2019Wells Fargo & CoDowngradeOutperform ➝ Market Perform$24.00 ➝ $16.00High
9/30/2019Stifel NicolausInitiated CoverageBuy$27.00High
9/16/2019Piper Jaffray CompaniesLower Price TargetOverweight$30.00 ➝ $28.00Low
8/9/2019BTIG ResearchInitiated CoverageBuy ➝ Buy$27.00High
8/7/2019WedbushBoost Price TargetOutperform$21.00 ➝ $26.00High
7/22/2019Cantor FitzgeraldInitiated CoverageOverweight ➝ Overweight$32.00 ➝ $32.00High
7/12/2019CIBCInitiated CoverageOutperform ➝ Outperform$27.00High
7/12/2019OppenheimerInitiated CoverageOutperform$27.00 ➝ $27.00High
6/7/2019Roth CapitalInitiated CoverageNeutral ➝ Neutral$20.00 ➝ $20.00Medium
5/30/2019GuggenheimInitiated CoverageBuy$25.00High
5/24/2019CitigroupReiterated RatingBuy ➝ Buy$20.00 ➝ $26.00Low
3/28/2019Svb LeerinkInitiated CoverageOutperform$20.00Medium
3/28/2019Leerink SwannInitiated CoverageOutperform$20.00Medium
1/3/2019StephensDowngradeOverweight ➝ EqualMedium
11/5/2018Jefferies Financial GroupInitiated CoverageBuy ➝ Buy$17.00Low
8/7/2018HC WainwrightReiterated RatingHold$12.00High
3/6/2018UBS GroupDowngradeOutperform ➝ Market PerformHigh
12/12/2017Raymond JamesReiterated RatingBuyMedium
(Data available from 11/19/2017 forward)
This page was last updated on 11/19/2019 by MarketBeat.com Staff

Featured Article: Holder of Record

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel